Share on StockTwits
 

AMAG Pharmaceuticals (NASDAQ:AMAG) Insider Christopher White sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $23.90, for a total value of $119,500.00. Following the completion of the transaction, the insider now directly owns 28,834 shares of the company’s stock, valued at approximately $689,133. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

AMAG has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, December 24th. They now have a $29.40 price target on the stock. Separately, analysts at Summer Street reiterated a “buy” rating on shares of AMAG Pharmaceuticals in a research note to investors on Thursday, October 24th. They now have a $43.00 price target on the stock, up previously from $31.00. Finally, analysts at Robert W. Baird upgraded shares of AMAG Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, October 18th. They now have a $26.00 price target on the stock, up previously from $25.00. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $25.91.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.21% during mid-day trading on Tuesday, hitting $23.98. 447,398 shares of the company’s stock traded hands. AMAG Pharmaceuticals has a 1-year low of $15.00 and a 1-year high of $28.42. The stock’s 50-day moving average is $24.14 and its 200-day moving average is $23.49. The company’s market cap is $521.2 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings data on Thursday, October 17th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.11. The company had revenue of $21.60 million for the quarter, compared to the consensus estimate of $20.37 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. The company’s revenue for the quarter was up 21.8% on a year-over-year basis. On average, analysts predict that AMAG Pharmaceuticals will post $-0.34 earnings per share for the current fiscal year.

AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.